Oxford, UK, 16 October 2013 Oxford Cancer Biomarkers has appointed David Oxlade as Chairman, a key growth milestone for the company which aims to benefit cancer patients through development of tests that allow medicines to be personalised.
Founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University, Oxford Cancer Biomarkers uses its proprietary platform CancerNav®, to rapidly generate predictive biomarkers for cancer drugs. The company has a strategic relationship with Quintiles in the biomarker space.
“We are delighted to welcome David Oxlade to Oxford Cancer Biomarkers, said Nick McCooke, CEO. His experience in building successful biotechnology businesses is particularly relevant as the Company expects to achieve substantial growth over the coming years”.
David is currently Chairman of TranScrip Partners LLP, base4innovation Ltd, and Kirkstall Ltd and previously a Non-Executive Director of Cobra Biologicals and Chairman of BioAnalab Ltd. Until 2005 David was CEO of Xenova Group plc, a LSE and NASDAQ listed oncology focused drug discov-ery and development company. Prior to joining Xenova Group, David was President of Syva Com-pany, the medical diagnostics’ business based in San Jose, California. Earlier he worked for ICI Pharmaceuticals, now AstraZeneca, during which time he oversaw the launch of Cellmark Diagnostics and its identity and forensic testing business ‘DNA Fingerprinting’ and for 14 years was with Boehringer Mannheim GmBH, now part of Roche, in Europe and the Far East.
He is an Honorary Fellow of Brunel University, a previous member of the Emerging Enterprise Council of EuropaBio and of the Bioscience Leadership Council until 2004. David Chaired the European Working Group of the Bioscience Innovation and Growth Team charged with setting out a 10 year agenda for developing the UK’s bioscience industry.
David commented: “I’m excited to be joining Oxford Cancer Biomarkers at this important stage of its development. The company has great potential, leveraging both its novel platform and its unique relationship with Quintiles, and I look forward to helping this to be fully realised”.
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Its unique platform, CancerNav®, isolates biomarkers which allow drugs to be tailored to the disease. It is a spin-out of the University of Oxford and is located on the Oxford Science Park. For more information, please visit www.oxfordcancerbiomarkers.com.
Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.